Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.

By S. Leucht, C. Corves, D. Arbter, R. Engel, Chunbo Li, John M. Davis. The Lancet, 2009

1,861 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. (2010, result): “The available empirical evidence continues to support the use of clozapine in people who have not responded to adequate treatment with FGAs.1,2 There is new evidence to suggest that clozapine is more effective than other SGAs in people who have failed to adequately respond to either an FGA or SGA.9,”
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance (2012, methodology): “…as haloperidol and perazine in the treatment of acute schizophrenia (Dieterle et al. 1991; Fleischhacker et al. 1989; Hwang et al. 2001; Klieser et al. 1991; Leucht et al. 2009b; Petit et al. 1996; Wetzel et al. 1991), and more effective compared to placebo and chlorpromazine (Cooper et al. 2000b).”
Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder (2015, result): “among antipsychotics, that has been confirmed in different studies and meta-analyses (11,23-33).”